Analytical Research & Development on Genotoxic Impurities

Genotoxic impurities (GTIs) pharmaceutical products may pose a considerable risk to patients safety due to their potential to interact with DNA and induce mutations, carcinogenicity, or other adverse effects. These impurities often arise during active pharmaceutical ingredient (API) synthesis from raw materials, intermediates, solvents, catalysts, or by-products. Their detection and control represent a critical challenge in drug development because of their structural diversity, instability, and the need for ultra-trace quantification. Regulatory authorities, including the ICH, USFDA, and EMA, have established stringent guidelines to identify, monitor, and control GTIs, with techniques like the Threshold of Toxicological Concern (TTC) and classification of impurities depends on mutagenic potential. Analytical advancements, particularly in Chromatographic methods including GC, LC-MS, UPLC, and HPLC have greatly improved analytical sensitivity, allowing more accurate detection and quantification of compounds, and robustness for GTI detection at ppm levels. Complementary strategies, including in-silico assessments, structural alerts, and toxicological evaluations, further enhance impurity profiling. This review highlights the sources, classifications, regulatory perspectives, assessment strategies, and analytical methodologies vital to guarantee pharmaceutical products' efficacy, safety, and quality, it is essential to minimize risks associated with genotoxic impurities (GTIs).